TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25062747

Group type: EXPERIMENTAL
Intervention: internet-based cognitive-behavioural therapy (iCBT)
Number of subjects: 212

Group type: COMPARATOR
Intervention: internet-based therapist-assisted progressive relaxation training (iPRT)
Number of subjects: 212
Study: 22158066

Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 607

Group type: COMPARATOR
Intervention: Ingesting ≥1 hypertension medication at bedtime
Number of subjects: 607
Study: 20120778

Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Losartan (200 mg/day)
Number of subjects: 18
Study: 17473072

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15215284

Group type: EXPERIMENTAL
Intervention: Weight loss of >=5% in any month
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Average random fluctuation in weight
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Monthly weight fluctuations
Number of subjects: 900
Study: 11215231

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml added to 1% propofol 20 ml (Group L)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline 2 ml added to 1% propofol 20 ml (Group S)
Number of subjects: 34
Study: 9099660

Group type: EXPERIMENTAL
Intervention: Bedside presentations
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conference-room presentations
Number of subjects: 182
Study: 8157036

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg b.d. for 12 weeks and fluvastatin 20 mg AM + 40 mg PM for an additional 12 weeks (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg qPM during the entire study (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of Group A (60 mg) vs Group B (40 mg qPM)
Number of subjects: 52
Study: 3093221

Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 31753271

Group type: EXPERIMENTAL
Intervention: Traffic light warning label
Number of subjects: 10412

Group type: EXPERIMENTAL
Intervention: Red stop sign warning label
Number of subjects: 10412

Group type: COMPARATOR
Intervention: Sodium warning labels (various designs)
Number of subjects: 10412
Study: 28264693

Group type: EXPERIMENTAL
Intervention: Tailored programme for implementing recommendations for multimorbid patients with polypharmacy; includes structured medication counselling, medication lists, and medication reviews.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 25669315

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 19

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 19
Study: 23022750

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the left posterior middle frontal gyrus (EEG electrode location F3) with an intensity of 110% of the individual resting motor threshold (RMT) for 15 sessions
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 47
Study: 20950914

Group type: EXPERIMENTAL
Intervention: Single suture technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple suture technique
Number of subjects: 50
Study: 18039681

Group type: EXPERIMENTAL
Intervention: Step-down treatment (COBRA regimen: sulphasalazine 2 g daily, methotrexate 15 mg weekly, oral prednisolone starting at 60 mg daily, tapering to 7.5 mg over 6 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Step-up treatment (DMARD monotherapy)
Number of subjects: 71
Study: 16413428

Group type: EXPERIMENTAL
Intervention: 0.1 mg ddAVP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2 mg ddAVP
Number of subjects: 10
Study: 12762270

Group type: EXPERIMENTAL
Intervention: Clinical trial patients
Number of subjects: 53859
Study: 11216493

Group type: EXPERIMENTAL
Intervention: Soy protein containing isoflavones (ISP+)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Soy protein with low isoflavone content (ISP‐)
Number of subjects: 81
Study: 9328363

Group type: COMPARATOR
Intervention: Low-dose rHuEPO (1,500 U intravenously three times a week for 26 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-dose rHuEPO plus nandrolone decanoate (100 mg intramuscularly weekly)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 19
Study: 8405026

Group type: EXPERIMENTAL
Intervention: Pinacidil 0.1 mg/kg IV
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3533372

Group type: EXPERIMENTAL
Intervention: Piretanide (24 mg daily for 28 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 38
Study: 31444820

Group type: EXPERIMENTAL
Intervention: S1 implants
Number of subjects: 64

Group type: COMPARATOR
Intervention: S2 implants
Number of subjects: 64
Study: 30464694

Group type: EXPERIMENTAL
Intervention: Preoperative biliary decompression (pbd) before article publication
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Preoperative biliary decompression (pbd) after article publication
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Patients seen preoperatively by a gastroenterologist
Number of subjects: 1997
Study: 28690083

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 26341121

Group type: EXPERIMENTAL
Intervention: High ApRot (>4.0°, n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low ApRot (≤4.0°, n = 41)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ApRot ≥ 6.0°
Number of subjects: 82
Study: 23965696

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25% bupivacaine (nerve block of the infrapatellar branch of the saphenous nerve)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 20505016

Group type: EXPERIMENTAL
Intervention: Eating Competence (EC)
Number of subjects: 638
Study: 18216523

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy followed by axillary lymph node dissection (ALND) only if SLN was metastatic (SLN arm)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND arm)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 697
Study: 16313908

Group type: EXPERIMENTAL
Intervention: Diet/Exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 37
Study: 14708961

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination with other drugs (cefepime, glycopeptide, linezolid)
Number of subjects: 0
Study: 10631626

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3166044

Group type: EXPERIMENTAL
Intervention: Midazolam sedation during local anesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Local anesthesia without midazolam sedation
Number of subjects: 32
Study: 30448787

Group type: EXPERIMENTAL
Intervention: Knowledge survey on stroke
Number of subjects: 143

Group type: COMPARATOR
Intervention: Family history of stroke
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Knowledge of stroke symptoms
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Response to suspected stroke
Number of subjects: 143
Study: 28039082

Group type: EXPERIMENTAL
Intervention: Intraoperative hyperoxic cerebral reperfusion (measured as every 10%·hour of hyperoxic cerebral reperfusion)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Hyperoxia prior to ischemia
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Increased concentrations of F2‐isoprostanes and isofurans at ICU admission
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Hyperoxic cerebral reperfusion
Number of subjects: 310
Study: 28532659

Group type: EXPERIMENTAL
Intervention: Immediate group (Strategies To Enhance Practice for Healthy Eating)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Delayed group (Strategies To Enhance Practice for Healthy Eating)
Number of subjects: 1700
Study: 24227728

Group type: EXPERIMENTAL
Intervention: Attended color on one side matched the ignored color on the opposite side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attended color on one side was different from the ignored color on the opposite side
Number of subjects: 0
Study: 21872843

Group type: EXPERIMENTAL
Intervention: 2 sets × 12 repetitions (REPS) of resistance training, 2 times per week, combined with aerobic training (cycle ergometry 6 times per week for 17±4 minutes and walking 5 times per week for 45 minutes)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 3 sets × 15 repetitions (REPS) of resistance training, 2 times per week, combined with aerobic training (cycle ergometry 6 times per week for 17±4 minutes and walking 5 times per week for 45 minutes)
Number of subjects: 295
Study: 19563201

Group type: EXPERIMENTAL
Intervention: New unified method of scalp acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Method with scalp projection areas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Method with standard treatment lines
Number of subjects: 0
Study: 17805064

Group type: EXPERIMENTAL
Intervention: Irinotecan, carboplatin, and imatinib (600 mg/day); treatment cycles were 28 days.
Number of subjects: 68
Study: 14675232

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 11445751

Group type: EXPERIMENTAL
Intervention: ACL-def patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 29
Study: 9507618

Group type: EXPERIMENTAL
Intervention: Intensive training of the cervical musculature
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment regimen
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study: 8589024

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days
Number of subjects: 14
Study: 2102134

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study: 224691

Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 46
Study: 31823525

Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 300 µg with high-fat meal
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 31075314

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (6 months, thrice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus education
Number of subjects: 0
Study: 27790726

Group type: COMPARATOR
Intervention: GP2015 (50 mg s.c. injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GP2015 via autoinjector (AI) (50 mg s.c. injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ETN (50 mg s.c. injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GP2015 via prefilled syringes (PFS) (50 mg s.c. injection)
Number of subjects: 0
Study: 26448615

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment (10 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 113
Study: 23745980

Group type: EXPERIMENTAL
Intervention: Conventional brackets (CBs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLBs)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (comparison between CB and SLB)
Number of subjects: 38
Study: 21828950

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) in BOS (+) group (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) in BOS (−) group (n = 4)
Number of subjects: 8
Study: 19854375

Group type: EXPERIMENTAL
Intervention: Krill oil (2 g/d)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Menhaden oil (2 g/d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Menhaden oil
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 76
Study: 16723614

Group type: EXPERIMENTAL
Intervention: Primary peritoneal drainage
Number of subjects: 117

Group type: COMPARATOR
Intervention: Laparotomy with bowel resection
Number of subjects: 117
Study: 15566659

Group type: EXPERIMENTAL
Intervention: 120 mg pamidronate (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 90 mg pamidronate (group B)
Number of subjects: 90
Study: 11378834

Group type: EXPERIMENTAL
Intervention: Non-dippers (n = 9)
Number of subjects: 16
Study: 9217246

Group type: EXPERIMENTAL
Intervention: Virend (15% ointment)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7934110

Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery bypass grafts
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts in group 1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery grafts in group 1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery bypass grafts in group 2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery grafts in group 2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Operative mortality
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarcts
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sternal wound infections
Number of subjects: 80
Study: 2906474

Group type: EXPERIMENTAL
Intervention: Olsalazine (0.75, 1.5, or 3 g daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Olsalazine (1.5 g and 3 g daily)
Number of subjects: 66
Study: 30231801

Group type: EXPERIMENTAL
Intervention: 5% added sugar (AS) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 25% added sugar (AS) diet
Number of subjects: 33
Study: 27266517

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Cymbopogon flexuosus, Thymus zygis and Rosmarinus officinalis)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 46
Study: 25542304

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22459101

Group type: COMPARATOR
Intervention: Tricompartmental knee arthroplasty (TKA)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Hip resurfacing (HR)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Knee arthroplasties (TKA and UKA)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Hip arthroplasties (THA and HR)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 347
Study: 19789443

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin <70 g/L)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin <95 g/L)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 125
Study: 18609051

Group type: EXPERIMENTAL
Intervention: Liberal fluid prescription (30-35 ml/kg body weight/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Restrictive fluid prescription (maximum fluid intake of 1.5 L/day)
Number of subjects: 74
Study: 12641302

Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical background and literature review
Number of subjects: 0
Study: 11018580

Group type: EXPERIMENTAL
Intervention: Various strategies to enhance adherence in randomized controlled trials
Number of subjects: 0
Study: 8987919

Group type: EXPERIMENTAL
Intervention: Vaginal approach with bilateral sacrospinous vault suspension and paravaginal repair
Number of subjects: 88

Group type: COMPARATOR
Intervention: Abdominal approach with colposacral suspension and paravaginal repair
Number of subjects: 88
Study: 1455374

Group type: EXPERIMENTAL
Intervention: Pulse therapy with methylprednisolone 25‐30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4‐0.5 g/sq. m BSA on the 3rd day, repeated quarterly for 12 months (Group 1 and Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No pulse therapy (Group 3)
Number of subjects: 30
Study: 6147843

Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 28557854

Group type: EXPERIMENTAL
Intervention: Combined bodyweight, mobility, and free-weights training (CBT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bodyweight and mobility training (BMT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physical education class (CON)
Number of subjects: 39
Study: 30509308

Group type: EXPERIMENTAL
Intervention: olanzapine, risperidone, and paliperidone
Number of subjects: 111
Study: 26405064

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25269124

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (n = 32)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Present centered therapy (n = 13)
Number of subjects: 45
Study: 22020317

Group type: EXPERIMENTAL
Intervention: S-1 administered under fed conditions
Number of subjects: 55

Group type: COMPARATOR
Intervention: S-1 administered under fasting conditions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: S-1 with PPI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: S-1 under fasting conditions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: S-1 under fed conditions
Number of subjects: 55
Study: 19710195

Group type: EXPERIMENTAL
Intervention: Milk group (3-5 portions of dairy products daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (maintained habitual diet)
Number of subjects: 121
Study: 17261227

Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (≥ 28 g of walnuts per day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control diet (≥ 2 g of walnuts per day)
Number of subjects: 87
Study: 15330755

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (1 g of L‐ascorbate, 400 IU of D,L‐alpha‐tocopherol acetate, 600 mg of alpha‐lipoic acid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (pooled placebo+antioxidant)
Number of subjects: 16
Study: 11242480

Group type: EXPERIMENTAL
Intervention: Vegan diet (n=16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (n=13)
Number of subjects: 29
Study: 9554641

Group type: EXPERIMENTAL
Intervention: High-frequency oral airway oscillation (frequency 8 Hz; I:E ratio 9:1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-frequency oral airway oscillation (frequency 14 Hz; I:E ratio 8:1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (frequency 3 Hz; I:E ratio 4:1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (frequency 16 Hz; I:E ratio 1:1, alternating with frequency 1.5 Hz, I:E ratio 6:1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional chest physical therapy (CPT)
Number of subjects: 14
Study: 8066514

Group type: EXPERIMENTAL
Intervention: Intensive physical and psychosocial training program
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 293
Study: 3408634

Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 10/170
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 16/260
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 31452148

Group type: EXPERIMENTAL
Intervention: HIV stigma reduction intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: breast cancer education
Number of subjects: 239
Study: 29577798

Group type: EXPERIMENTAL
Intervention: Art Intervention Program (12 sessions, once a week)
Number of subjects: 17
Study: 27327502

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 201
Study: 24897743

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT group) - six sessions of a standardized hospital-based physical therapy program
Number of subjects: 61

Group type: COMPARATOR
Intervention: No further treatment (no-PT group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT group)
Number of subjects: 61
Study: 21767018

Group type: EXPERIMENTAL
Intervention: HIV-test promotion messages
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 1052

Group type: COMPARATOR
Intervention: No message control
Number of subjects: 1052
Study: 20722677

Group type: EXPERIMENTAL
Intervention: Tramadol (37.5 mg)/Acetaminophen (325 mg)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Gabapentin (300 mg)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen
Number of subjects: 163

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 163